Chlorthalidone vs hydrochlorothiazide
Reading Document
Medical Text Search
chlorthalidone vs hydrochlorothiazide comparison efficacy hypertension
Medical Text Search
thiazide diuretic pharmacology mechanism duration half-life
GradeResponse
GradeResponse
Chlorthalidone vs. Hydrochlorothiazide (HCTZ)
Both are classified as thiazide-type diuretics used primarily for hypertension. Despite frequent interchangeability in clinical practice, they differ meaningfully in pharmacology and some outcomes data.
Pharmacology
| Property | Chlorthalidone | HCTZ |
|---|---|---|
| Chemical class | Thiazide-like (sulfonamide, lacks benzothiadiazine ring) | True thiazide (benzothiadiazine ring) |
| Half-life | ~40–60 hours | ~6–15 hours |
| Duration of action | ~48–72 hours | ~12–24 hours |
| Relative potency | ~1.5–2× more potent per mg | Reference |
| Typical dose | 12.5–25 mg daily | 12.5–50 mg daily |
The longer half-life of chlorthalidone provides more sustained 24-hour BP control, including nocturnal coverage, which is clinically relevant because early-morning BP surges are associated with cardiovascular (CV) events.
Mechanism of Action
Both act by inhibiting the Na⁺/Cl⁻ cotransporter (NCC) in the distal convoluted tubule, reducing sodium and water reabsorption. Long-term antihypertensive effect is primarily through arterial vasodilation (reduced peripheral resistance), not just volume depletion.
Efficacy in Hypertension
- The ACC/AHA 2017 Guidelines (Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults, p. 35) acknowledge differences in potency and half-life between agents and note that thiazide-like diuretics (chlorthalidone, indapamide) are preferred for resistant hypertension due to greater efficacy.
- In standard hypertension, both agents are generally considered interchangeable, and guidelines allow clinicians to choose among them.
- Chlorthalidone is the agent used in landmark trials — ALLHAT being the most prominent — which established thiazide-type diuretics as first-line agents. HCTZ was not the study drug in these large outcome trials, a frequently cited limitation of HCTZ's evidence base.
Head-to-Head Evidence
A recent RCT (referenced in Management of Elevated Blood Pressure and Hypertension, p. 69) directly comparing the two agents in a population that likely included a substantial proportion of resistant hypertension:
- No significant difference in systolic BP or overall CV outcomes between chlorthalidone and HCTZ
- In the subgroup with prior CVD, there was a strong trend toward benefit with chlorthalidone on CV outcomes
- Hypokalemia was significantly more common with chlorthalidone
This trial tempered enthusiasm for a blanket preference for chlorthalidone, though the CV subgroup trend keeps the debate alive.
Adverse Effects
| Effect | Chlorthalidone | HCTZ |
|---|---|---|
| Hypokalemia | More common (higher risk) | Less common |
| Hyponatremia | Both (similar) | Both |
| Hyperuricemia/gout | Both | Both |
| Hyperglycemia | Both | Both |
| Hyperlipidemia | Minimal, both | Minimal, both |
| Erectile dysfunction | Both | Both |
The excess hypokalemia risk with chlorthalidone is clinically important — potassium monitoring is warranted, particularly at higher doses.
Special Populations
- Resistant hypertension / CKD with volume expansion: Chlorthalidone preferred due to greater potency and longer duration (Management of Elevated Blood Pressure and Hypertension, p. 69). However, in eGFR < 30 mL/min/1.73 m², loop diuretics are necessary, as thiazide-type agents lose efficacy.
- Heart failure: Loop diuretics are primary; thiazides sometimes added for synergy.
- Osteoporosis: Both reduce urinary calcium excretion — potential bone benefit.
- Kidney stones (calcium oxalate): Both reduce hypercalciuria.
Bottom Line
| Consideration | Preferred Agent |
|---|---|
| Landmark RCT evidence (ALLHAT) | Chlorthalidone |
| Resistant hypertension | Chlorthalidone |
| Prior CVD (trend only) | Chlorthalidone |
| Lower hypokalemia risk | HCTZ |
| Standard uncomplicated hypertension | Either (guideline-acceptable) |
| eGFR < 30 | Neither — use loop diuretic |
Chlorthalidone has a stronger pharmacological rationale (longer action, greater potency) and more robust outcomes evidence. HCTZ is more widely prescribed historically but lacks the landmark trial data. The head-to-head trial showing no difference in overall CV outcomes has complicated the picture, but most guidelines still favor chlorthalidone for resistant hypertension, and many hypertension specialists prefer it as a general first choice for the thiazide class.
This is a shared conversation. Sign in to Orris to start your own chat.